Share on StockTwits

Stock analysts at Bank of America assumed coverage on shares of Roka Bioscience (NASDAQ:ROKA) in a report issued on Monday. The firm set a “buy” rating on the stock.

Shares of Roka Bioscience (NASDAQ:ROKA) traded up 8.67% during mid-day trading on Monday, hitting $11.40. 51,947 shares of the company’s stock traded hands. Roka Bioscience has a 1-year low of $9.15 and a 1-year high of $13.00. The stock’s 50-day moving average is $10. and its 200-day moving average is $10.. The company’s market cap is $201.0 million.

Roka Bioscience (NASDAQ:ROKA) last announced its earnings results on Monday, August 11th. The company reported ($11.28) EPS for the quarter. The company had revenue of $1.40 million for the quarter.

Several other analysts have also recently commented on the stock. Analysts at Cowen and Company initiated coverage on shares of Roka Bioscience in a research note on Monday. They set an “outperform” rating and a $13.00 price target on the stock. Separately, analysts at Wedbush initiated coverage on shares of Roka Bioscience in a research note on Monday. They set an “outperform” rating and a $15.00 price target on the stock. Finally, analysts at Leerink Swann initiated coverage on shares of Roka Bioscience in a research note on Monday. They set an “outperform” rating and a $13.00 price target on the stock.

Roka Bioscience, Inc is a molecular diagnostics company. The Company focuses on advanced testing solutions for the detection of foodborne pathogens.

Receive News & Ratings for Roka Bioscience Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roka Bioscience Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.